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ABSTRACT 
Neuronal nAChR upregulation is the hallmark of chronic nicotine exposure.  
Neuroplasticity to abused drugs, however, depends on whether their administration is 
forced by the experimenter or is under the control of the experimental animal.   
Neuroadaptation to chronic nicotine self-administration was examined with a yoked-control 
paradigm, using nose-poking as the operating procedure.  Freely moving C57BL/6J mice 
that responded for 0.03 mg/kg/infusion of intravenous nicotine under a continuous schedule 
of reinforcement (FR-1), had control over the rate and amount of drug intake that a yoked 
littermate passively received (n=11).  The impact of response dependency on 
neurobiological changes in nicotinic and dopaminergic systems was subsequently assessed 
using quantitative autoradiography. Cytisine-sensitive [125I]epibatidine binding, 
[3H]SCH23390, [3H]raclopride, and [3H]mazindol were used to label nAChRs with α4β2* 
subtype properties, D1 and D2 dopaminergic receptors, and dopamine transporters, 
respectively. During a period of 12 days, self-administration was reliably initiated and 
maintained in animals receiving response-contingent nicotine.  Region specific changes in 
the density of α4β2* nAChRs were found to be dependent on the contingency of nicotine 
treatment.  Higher levels of α4β2* receptor binding were observed in the dorsal lateral 
geniculate nucleus and the ventral tegmental area of self-administering mice, compared to 
non-contingent animals.  Moreover, response-independent increases in D2 binding were 
observed following chronic nicotine administration.  No change in D1 and DAT binding 
was observed among groups.  These findings indicate regional specific alterations in the 
regulation of the nicotinic cholinergic system following contingent and non-contingent 
nicotine exposure, and underline the importance of response dependency on the 
development of nicotine addiction. 
  
Keywords: autoradiography, mouse, nicotine, operant contingency, self-administration                        
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INTRODUCTION 
Nicotine exerts its reinforcing effects by binding in the brain to its corresponding 
pharmacological targets, the neuronal nicotinic receptors (nAChRs).  These are a 
heterogeneous family of pentameric structures, formed by the assembly of five α and β 
subunits.  To date twelve different subunits have been identified (α2-α10, β2-β4), 
whose combinations give rise to nAChRs with unique pharmacological properties and 
distinct topographical distribution (reviewed in Gotti and Clementi, 2004).  This 
prominent heterogeneity mediates nicotine’s abuse related potential, as the drug 
has been shown to differentially coordinate the function of distinct nAChR 
subtypes, thereby stimulating reward-related signaling in areas of the brain that 
mediate reinforcement (Pidoplichko et al., 1997; Mansvelder and McGehee, 2000; 
Mansvelder et al., 2002).  Nevertheless, the transition from the activation of individual 
nAChR subpopulations to addiction is a complicated and multistage process, which 
involves the acquisition, maintenance, extinction, and reinstatement of drug-taking.  
Therefore, behavioural paradigms that model distinct stages of addictive 
behaviour provide important methodological tools for determining the 
neurobiological substrates that mediate the progression to nicotine addiction. 
.   
The observation that the administration of nicotine leads to increased brain nAChR 
density in cigarette smokers (Perry et al., 1999) and in animal models of nicotine 
consumption (Marks et al., 1983; Schwartz and Kellar, 1983) constitutes the hallmark 
of chronic nicotine exposure.  This unusual phenomenon of agonist-induced 
receptor upregulation is considered to form the basis for many of nicotine’s 
abuse-related effects, including tolerance and behavioural sensitisation (Tapper et 
al., 2004; Nashmi et al., 2007).  Of the multiple nicotinic subtypes that exist in the 
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mammalian brain, α4β2* receptors are abundantly expressed throughout the central 
nervous system, and they readily upregulate following exposure to nicotine, compared 
with other nAChR subtypes (Nguyen et al., 2003; Marks et al., 2004).  As shown in a 
conditioned place preference paradigm, a mutation that renders α4 subunits 
hypersensitive to agonists creates mice that are more susceptible to nicotine 
reinforcement than wild type animals (Tapper et al., 2004).  Moreover, deletion of the 
β2 subunit gene attenuates nicotine self-administration (Picciotto et al., 1998) and its 
re-expression in the VTA of β2 subunit knockout animals re-establishes the behaviour 
(Maskos et al., 2005).  Altogether, these data demonstrate an important role for α4β2* 
nAChRs in nicotine addiction. 
 
Among the paradigms employed to model different aspects of drug reinforcement, self-
administration has been favoured as the most direct way of investigating the 
behavioural and neurobiological processes that lead to addiction.  Its face validity is 
supported by increasing evidence, which suggests that drugs of abuse exert different 
effects, depending on whether their administration is forced by the experimenter or is 
under the control of the experimental animal (reviewed in Jacobs et al., 2003).  The 
yoked-control paradigm has been particularly designed to examine differences 
produced by the active or passive drug administration.  In this model, self-
administering animals have control over the rate and amount of drug intake that a 
yoked littermate passively receives in an identical environment.  Thus, potential 
differences in the consequences of active versus passive administration can be 
attributed to having control over the pattern of drug exposure.  To determine the extent 
to which nicotine-induced neuroadaptation is the consequence of the drug’s direct 
pharmacological action or the result of the contingency between a subject’s response 
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and the delivery of a reinforcer, a yoked-control paradigm of chronic nicotine 
administration in mice was employed, using nose-poking as the operating response.  
The latter is considered to more naturally mimic smoking behaviour in mice, requiring 
less motor and motivational output than lever pressing responding (Pons et al., 2008).  
Subsequently, we examined the consequences of active versus passive nicotine 
exposure on the nicotinic cholinergic and dopaminergic systems of C57BL/6J mice by 
means of quantitative autoradiography of cytisine-sensitive heteromeric nicotinic 
receptors, D1 and D2 dopaminergic receptors, and of dopamine transporters, in an 
effort to clarify the neurochemical determinants that mediate the acquisition of nicotine 
self-administration.  
                                   
MATERIALS AND METHODS 
Self administration paradigm 
Animals 
C57BL/6J male mice (Charles River, France), weighing 24-26 g at the beginning of 
the study were used.  Animals were housed individually in controlled laboratory 
conditions under a reversed 13h/11h dark/light cycle (lights off at 7.30h, lights on at 
20.30h), with the temperature maintained at 21 ± 1 ºC, and humidity at 55 ± 10%.  The 
circadian cycle employed allowed us to maximize the time required to perform 
the experimental manipulations without substantial modifications of the 12h/12h 
cycle commonly used.  Mice were tested during the dark phase of the dark/light cycle.  
Food and water were available ad libitum, except during the experimental sessions.  
Animal procedures were conducted in accordance with the guidelines of the European 
Communities Directive 86/609/EEC regulating animal research, and approved by the 
local ethical committee (CEEA-IMAS-UPF). 
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Surgery and self-administration procedure 
Mice were anaesthetised with a mixture of ketamine (100 mg/kg; Imalgène 1000; 
Rhône Mérieux, Lyon, France) and xylazine (20 mg/kg; Sigma, Madrid, Spain), and 
then implanted with indwelling i.v. catheters as previously described (Soria et al., 
2005).  Following surgery, all incisions were sutured and coated with antibiotic 
ointment (Bactroban, GlaxoSmithKline, Spain), and animals were allowed to recover 
for 3 days.  Mice were subsequently randomly assigned to contingent or yoked groups.   
 
Drug self-administration experiments were conducted in mouse operant chambers 
(Model ENV-307A-CT, Medical Associates, Georgia, VT, USA), housed in sound- 
and light-attenuated boxes that were equipped with fans to provide ventilation and 
white noise.  The house light was on at the beginning of the session for 3 sec and off 
during the remaining time.  The chambers were equipped with two holes, of which one 
was selected as the active and the other as the inactive hole.  Responding in both holes 
was recorded for all groups, throughout the experiments.  The contingent group was 
trained to self-administer nicotine (0.03 mg/kg/infusion delivered in a volume of 23.5 
μl over 2s; Sigma, Madrid, Spain) in single daily 1-h sessions for a period of 12 days.  
Even though nicotine self-administration is already acquired after 10 days of 
training (Martín-García et al. 2009, Plaza-Zabala et al. 2010), we run the animals 
for 2 additional days in order to maximize stability in the observed behaviour and 
in the possible neural modifications under study.  Previous experiments in our 
laboratory indicated that a priming injection at the beginning of the session 
facilitates the acquisition of nicotine self-administration (Martin-Garcia et al., 
2009; Plaza-Zabala et al., 2010), so each session started with a priming injection of 
nicotine or saline (depending on the group).  Acquisition of nicotine self-
Athanasios Metaxas 6
administration was conducted under a fixed ratio 1 (FR-1) schedule of reinforcement; 
one poke in the active nose hole resulted in one nicotine infusion, while nose poking in 
the inactive hole had no programmed consequences.  A 10 sec time-out period was 
established following each nicotine infusion.  During this period, responses on the 
active and inactive holes were recorded but had no programmed consequences.  The 
session was terminated after 50 infusions had been delivered, or after one hour, 
whichever occurred first.  Each contingent mouse was connected to two animals, one 
in the yoked nicotine and one in the yoked saline groups.  Yoked mice passively 
received the same number of drug infusions as compared with their self-administration 
partners, at identical times during each session. Their nose-poking activity on the 
active and inactive holes had no consequences.  A stimulus light located above the 
active hole was paired with the delivery of nicotine or saline, according to the response 
of the contingent mouse.  The patency of the intravenous catheters was evaluated 
periodically, and whenever drug self-administration behaviour appeared to deviate 
dramatically from that observed previously, by the infusion of 0.1 ml of thiobarbital (5 
mg/ml) through the catheter.  If prominent signs of anaesthesia were not apparent 
within 3 sec of the infusion, the mouse and its corresponding data were removed 
from the experiment.  The criteria for the acquisition of self-administration behaviour 
have been described previously (Orejarena et al., 2009; Trigo et al., 2009), and were 
achieved when all of the following conditions had been met: a stable responding, with 
less than 20% deviation from the mean of the total number of reinforces earned in three 
consecutive sessions (80% of stability), at least 65% of responding on the active hole, 
and a minimum of 4 nicotine infusions earned per experimental session.  After each 
session, animals were returned to their home cages.  At the end of the study mice were 
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killed and brains were rapidly removed and frozen for storage at –80 Cº for subsequent 
quantitative autoradiography studies. 
 
Quantitative receptor autoradiography 
Tissue sectioning was carried out at -21°C using a Zeiss Microm HM505E cryostat.  
20 µm frozen coronal sections were cut at 300 µm intervals, from rostral to caudal 
levels.  Quantitative autoradiography was performed in order to measure nicotinic 
receptors with α4β2* subtype properties, dopaminergic D1 and D2 receptors, and the 
dopamine transporters (DAT).  On the day of each experiment, sections were thawed 
and processed according to established protocols, with minor modifications (Javitch et 
al., 1984; Marks et al., 2002; Lena et al., 2004; Bailey et al., 2008).  All mice were 
used for quantitative autoradiography of nAChRs.  Dopaminergic receptor and 
transporter binding was performed in 3 self-administering mice that achieved 
acquisition criteria, 3 that did not, and their corresponding littermates (n=6 per 
group).  Multiple, adjacent sections from all groups were processed together in a 
paired binding protocol.  Radioligand bound sections were apposed to Kodak BioMax 
MR-1 film (Sigma-Aldrich, UK), along with appropriate microscale standards, to allow 
quantification.  All structures were identified by reference to the mouse brain atlas of 
Franklin and Paxinos, (2001), and analysed using a MCID image analyser (Image 
research, Linton, UK).   
 
For nicotinic receptor binding, sections were pre-incubated for 10 min at room 
temperature in Tris-HCl buffer, containing 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 
and 1 mM MgCl2, pH 7.4, followed by incubation with 100 pM [125I]epibatidine 
(specific activity, 2,200 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA) for 
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two hours at room temperature.  Determination of subtype-specific binding was 
performed using adjacent sections from each brain, in order to measure total 
[125I]epibatidine binding (no competing ligand), and [125I]epibatidine binding in the 
presence of 20 nM cytisine (Sigma-Aldrich, UK).  Competition of [125I]epibatidine 
binding by unlabeled cytisine has been used to reveal two subpopulations of nAChRs 
with high  and low affinity for cytisine, termed cytisine-sensitive and cytisine-resistant 
[125I]epibatidine binding sites, respectively.  The cytisine-sensitive [125I]epibatidine 
binding sites correspond to α4β2* nicotinic receptors (Marks et al., 1998; Whiteaker et 
al., 2000), and were calculated after the subtraction of cytisine-resistant from total 
[125I]epibatidine binding.  To determine non-specific binding, further adjacent 
sections were incubated with [125I]epibatidine in the presence of 300 µM of (–) 
nicotine hydrogen tartrate (Sigma-Aldrich, UK).  Incubations were terminated by two, 
ten minute washes into ice-cold 50 mM Tris-HCL buffer (pH 7.4), and a rapid rinse in 
ice-cold water.  Radioligand bound sections were apposed to film for 24h.  Structures 
of exceptionally high nAChR density, including the medial habenula, fasciculus 
retroflexus, and the interpeduncular nucleus were apposed for 6h, to avoid film 
saturation.  
 
For D1 and D2 receptor binding, all sections were first pre-incubated for 20 min in 50 
mM Tris–HCl buffer, pH 7.4, containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 
1 mM MgCl2, at room temperature.  For D1 binding, sections were then incubated for 
90 min in the same buffer, at room temperature, in the presence of 4 nM 
[3H]SCH23390 (specific activity, 70.3 Ci/mmol; PerkinElmer Life Sciences, Boston, 
MA, USA) and 1 μM mianserin, in order to avoid binding of [3H]SCH23390 to 5-HT2 
and 5-HT1c receptors.  To label D2 receptors, incubation was carried out for 60 min in 
Athanasios Metaxas 9
the presence of 4 nM [3H]raclopride (specific activity, 60.1 Ci/mmol; PerkinElmer Life 
Sciences, Boston, MA, USA), under identical pH and temperature conditions.  Non-
specific binding was determined on adjacent sections in the presence of 10 μM of cis-
flupenthixol for D1 receptors or 10 μM of sulpiride for D2 receptors.  The incubations 
were terminated by rapid rinses (6×1 min) in ice-cold 50 mM Tris–HCl buffer (pH 7.4) 
followed by a dip into ice-cold distilled water.  For D1 and D2 receptors, radioligand 
bound sections were apposed to film for 5 and 6 weeks, respectively. 
 
For the DAT, all slides were pre-incubated for 5 min at 4°C in 50 mM Tris-HCl buffer, 
pH 7.4, containing 300 mM NaCl and 5 mM KCl.  The slides were subsequently 
incubated at 4°C for 45 min in the same buffer, containing 4 nM [3H]mazindol 
(specific activity, 20.6 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA) and 
0.3 μM desipramine, to block the binding to norepinephrine uptake sites.  Non-specific 
binding was determined in the presence of 10 μM mazindol.  After incubation, sections 
were rinsed twice for 1 min in ice-cold Tris buffer, and briefly dipped in ice-cold 
distilled water.  Sections were apposed to film for 5 weeks. 
 
Statistical analysis  
Behavioural results were analysed using a mixed-design multivariate analysis of 
variance (MANOVA), with group (contingent, non-contingent, and saline-treated) as 
the between-subjects variable.  Daily sessions and hole (active vs. inactive) represented 
the within-subjects variable.  Overall interactions were further analysed using the 
Newman-Keuls post-hoc test, when the initial P value was smaller than 0.05.  All the 
results are expressed as mean ± standard error of the mean (SEM).   
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For quantitative autoradiography, the mean±SEM of radioligand binding was 
calculated in each region for all three treatment groups, as previously described 
(Kitchen et al., 1997).  Two-way ANOVA for the factors treatment and region was 
carried out in order to compare quantitative measurements of autoradiographic binding 
in brain areas of contingent, non-contingent, and saline-treated animals.  Structures of 
the habenulo-interpeduncular pathway were quantified using the 6 h exposure to film, 
due to the high densities of heteromeric nAChRs in this cholinergic system.  Therefore, 
comparisons between regions of exceptionally high nicotinic receptor density were 
performed using a separate two away ANOVA (independent factors treatment and 
region).  Quantitative differences in nicotinic and dopaminergic binding sites 
between self-administering mice that achieved acquisition criteria and those that 
did not were analysed using a separate two-way ANOVA, for the factors 
acquisition and region.  LSD post-hoc analysis was applied, when appropriate, to 
investigate differences in radioligand binding between groups in individual regions.   
 
All data were analysed using the Statistica software (StatSoft Inc., France). 
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RESULTS 
Nicotine self-administration 
Figure 1 shows the mean number of nose-pokes in the active and inactive holes, carried 
out by nicotine contingent, non-contingent and saline-treated animals under an FR-1 
schedule of reinforcement, for each of the 1hr daily self-administration sessions.  At 
the nicotine dose of 0.03 mg/kg/infusion, contingent mice started to discriminate 
between the active and inactive holes from the first training session (Figure 1A).  The 
percentage of animals that proceeded to complete all of the criteria for stable nicotine 
self-administration was 54.5% (six out of eleven), and the mean time of acquisition 
was 8.83±1.19 days.  On the contrary, nicotine- and saline- yoked mice did not 
discriminate between holes in any of the experimental sessions (Figure 1B and 1C).  
On days 1 and 2, the number of nose pokes was enhanced in all groups, compared to 
days 3-12.  The mean nicotine intake decreased from 0.38±0.01 mg/kg/hr on days 1 
and 2, to 0.22±0.01 mg/kg/hr for days 3-12.  Contingent mice showed a mean 
cumulative nicotine intake of 0.25±0.04 mg/kg/hr throughout the training sessions.  In 
the case of the animals that achieved acquisition criteria, the mean intake of nicotine 
during the last three days of self-administration was 0.35±0.09 mg/kg/hr.  The overall 
ANOVA revealed a statistically significant effect of the factors group (F2,58=12.0, 
P<0.001), time (F11, 638=15.2, P<0.001), and nose-poke (F1,58=22.6, P<0.001), as well 
as significant group x nose-poke interaction effects (F2,58=7.8, P<0.001).  Newman-
Keuls post-hoc analysis confirmed that the responses on the active and inactive nose-
pokes were significantly higher only in the contingent group and not in the yoked 
groups.    
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Quantitative receptor autoradiography 
Effects of response contingency on nAChR binding 
Quantitative autoradiography was conducted for α4β2* nAChRs, using 100 pM of 
[125I]epibatidine alone or in the presence of cytisine (20 nM).  The majority of mouse 
brain [125I]epibatidine binding sites were of the cytisine-sensitive, α4β2* subtype.  
Non-specific [125I]epibatidine binding was indistinguishable from film background 
(Figure 2). The density of cytisine-sensitive and cytisine-resistant [125I]epibatidine 
binding in brain regions of saline, contingent, and non-contingent mice is detailed for 
all areas analysed in Tables 1 and 2, respectively.  Figure 3 shows representative 
autoradiograms of [125I]epidatidine binding sites in coronal brain sections from 
saline and nicotine treated mice, cut at the level of the thalamus and of the ventral 
tegmental area. 
 
Significantly higher levels of α4β2* nAChRs were observed in the dorsal lateral 
geniculate nucleus (DLG) and the VTA of self-administering mice, compared to non-
contingent animals and to saline controls.  Contingent nicotine also increased cytisine-
sensitive [125I]epibatidine binding in the superficial gray layers of the superior 
colliculus (SuG) and certain thalamic nuclei, such as the ventral lateral geniculate 
nucleus (VLG), the posterior thalamic nuclear group (Po), and the lateral posterior 
thalamic nucleus (LPMR), compared to saline treatment.  In non-contingent animals, 
higher levels of α4β2* receptor binding were observed in the VLG and SuG compared 
to saline controls.  No differences in cytisine-sensitive [125I]epibatidine binding sites 
were detected between contingent mice that achieved acquisition criteria, and animals 
that did not stably respond for nicotine (F1,140=1.8, P>0.05).  For nAChRs with α4β2* 
nAChR properties, two-way ANOVA showed significant main effects of treatment 
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(F2,463=20.4, P<0.001) and region (F17,463=48.3, P<0.001), with no treatment x region 
interaction effects (F34,463=1.2, P>0.05).  LSD post hoc analysis confirmed significant, 
region specific differences in cytisine-sensitive [125I]epibatidine binding between self-
administering and nicotine-yoked mice in the DLG and the VTA.  Comparisons of 
cytisine-sensitive [125I]epibatidine binding measurements between structures of high 
nicotinic receptor density revealed no treatment (F2,43=0.3, P>0.05), and no treatment x 
region interaction effects  between groups (F4,43=0.2, P>0.05).    
 
Cytisine-resistant [125I]epibatidine binding sites represented the major nAChR 
population in areas of the habenulo-interpeduncular pathway, and the quantitative 
comparison of nAChR density in these brain regions revealed no treatment (F2,45=1.0, 
P>0.05) or treatment x region interaction effect (F4,45=0.5, P>0.05).  Cytisine-resistant 
binding in the rest of brain regions analysed was significantly lower in the SuG, the 
intermediate gray layer of the superior colliculus (InG), and the substantia nigra pars 
compacta (SNs) of nicotine yoked animals, compared to saline controls.  A lower level 
of cytisine-resistant binding was also observed in the InG of self-administering 
animals, compared to controls.  Two way ANOVA confirmed significant main effects 
of treatment (F2,463=3.0, P<0.05) and region (F17,463=216.8, P<0.001), with significant 
treatment x region interaction effects on cytisine-resistant receptor density (F34,463=1.5, 
P<0.05).  No differences were detected between nicotine-contingent and yoked mice, 
in any of the brain regions analysed (F1,140=2.0, P>0.05).   
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Effects of response contingency on dopaminergic D1 and D2 receptor, and on 
dopamine transporter binding  
Full quantification of dopaminergic D1 and D2 receptor binding, and of the dopamine 
transporters (DAT) was carried out on brain sections from all treatment groups, using 
[3H]SCH23390, [3H]raclopride, and [3H]mazindol, respectively.  For D2 receptor 
binding, two-way ANOVA revealed significant main effects of treatment (F2,95=6.1, 
P<0.01) and region (F6,95=74.4, P<0.001), with no significant treatment × region 
interaction effect (F12,95=0.3, P>0.05) (Table 3).  There was an overall increase in D2 
receptor binding across all regions, in both nicotine contingent and non-contingent 
mice, compared to saline controls.  However, post hoc comparison revealed no 
individual region significant increase among groups.  The small level of increase in D2 
receptor density was observed in self-administering animals, as well as in contingent 
mice that did not fulfil acquisition criteria (F1,24=0.0, P>0.05). 
 
Neither response-dependent, nor passively received nicotine had any significant effects 
on dopamine D1 receptor (F2,133=2.6, P>0.05) and dopamine transporter (DAT) binding 
(F2,105=2.0, P>0.05), compared with saline treatment (Tables 4&5).  Moreover, no 
changes in D1 receptor density (F1,36=0.2, P>0.05) and DAT binding (F1,28=1.1, 
P>0.05) were detected in brain sections from animals that stably responded for 
nicotine, compared to mice that did not achieve acquisition criteria.  Representative 
autoradiograms of dopaminergic receptor and transporter bindings in brain sections of 
nicotine contingent, yoked, and saline-treated animals are shown in Figure 4.                                               
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DISCUSSION 
Previous studies have shown that nicotine, at a concentration range between 0.01-0.05 
mg/kg/infusion, supports self-administration in diverse species, including humans 
(Henningfield et al., 1983), non-human primates (Goldberg et al., 1981) and rodents 
(Martellotta et al., 1995; Donny et al., 1998).  In agreement with this literature, we 
report here that freely moving C57BL/6J mice will chronically self-administer an 
optimal dose of response-dependent nicotine, using nose-poking as the operating 
procedure.  The yoked-control model of self-administration allows discriminating the 
neurobiological response that occurs as a result of the direct pharmacological effects of 
a drug, from neuroplasticity that is due to the contingency between a behavioural 
reaction and drug delivery.  By successfully applying this operant paradigm in mice, 
we reveal that differential neuroadaptation takes place in the nicotinic cholinergic 
system, depending on whether nicotine is administered actively or passively.  Indeed, 
cytisine-sensitive [125I]epibatidine binding differed between self-administering and 
nicotine-yoked animals in the ventral tegmental area (VTA) and the dorsal lateral 
geniculate nucleus (DLG), suggesting that these brain regions are critically involved in 
the processes relating to the acquisition and maintenance of nicotine self-
administration. 
 
The increased rate of self-administration observed on days 1 and 2 may be partly 
attributed to the novelty of the experimental procedure.  Similar patterns of increased 
intake during the initial phase of drug exposure have also been observed elsewhere 
(Mendizabal et al., 2006).  As early as on day 1, however, contingent mice were 
discriminating between the active and inactive hole, suggesting that the enhanced 
initial consumption may partly constitute a specific, nicotine-maintained effect on 
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behaviour.  In line with our findings, a pattern of escalated drug intake that levels off in 
subsequent sessions has also been observed in rats that chronically self-administer 
nicotine (O'Dell et al., 2007).  Out of a wide range of doses, acute self-
administration of nicotine in mice occurs around a narrow window of 
approximately 0.03 mg/kg/infusion, indicating that rodents will tightly regulate 
their amount of nicotine intake (Paterson et al., 2003; Pons et al., 2008).  Indeed, 
titration seems to be an important feature of nicotine self-administration across species, 
as both adult (Benowitz and Jacob, 1985) and adolescent (Kassel et al., 2007) smokers 
carefully control their nicotine levels in order to experience the reinforcing effects of 
the drug.  The observed enhanced initial rate of nicotine consumption may thus reflect 
a learning response at a given level of titration, which rapidly occurred within the first 
two experimental sessions.   
 
Following day 7, reliable drug-taking behaviour was observed in animals receiving 
response-dependent nicotine, which was maintained for the remainder of this 
experiment.  Response-contingent animals adjusted their behaviour to obtain a mean 
drug intake of approximately 0.25 mg/kg/session, which is within the range of nicotine 
chronically self-administered by rats (Donny et al., 1995; Kenny and Markou, 2006). 
As demonstrated by cytisine-sensitive [125I]epibatidine autoradiography, exposure to 
this nicotinic dose led to region-specific increases of α4β2* nAChRs in the brains of 
self-administering animals.  The upregulation displayed marked regional variability, 
with different areas of the brain participating and showing different sensitivity to 
upregulation.  In this respect, our findings are consistent with previous observations 
that experimenter-administered nicotine in rodents (Marks et al., 1983; Schwartz and 
Kellar, 1983; Nguyen et al., 2003), as well as nicotine self-administration by rats 
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(Parker et al., 2004), produces regional-specific increases in the density of nicotinic 
receptors.  The brain areas where contingent nicotine upregulated nAChRs have 
been shown to be affected by nicotine exposure following a variety of drug 
administration regimes, including tail vein infusion (Pauly et al., 1991), osmotic 
minipumps (Nguyen et al., 2003), oral administration (Sparks and Pauly, 1999), 
and continuous self-administration in the rat (Parker et al., 2004).  This suggests 
that the paradigm of nicotine self-administration we have employed is a valid 
model for the investigation of nicotine-induced neuroadaptation.  Substantial 
experimental work has established nAChR upregulation as the hallmark of chronic 
nicotine treatment.  Using intravenous nicotine infusion, it has been consistently 
demonstrated that nicotine-induced receptor upregulation is a dose and time dependent 
phenomenon, with the half maximal dose required to induce 50% of region-specific 
nAChR upregulation in mice being approximately 0.5 mg/kg/hr (Marks et al., 1991; 
Pauly et al., 1991; Marks et al., 2004).  In our paradigm, the mean daily amount of self-
administered and passively received nicotine was at 0.25 mg/kg/hr.  Therefore, the 
lack of pronounced upregulation in nicotine-yoked mice is in agreement with the 
dosing profile for drug induced nAChR increases, and underlines the significance 
of contingency in nicotinic neuroadaptation, since we observed α4β2* nAChR 
upregulation with smaller, albeit behaviourally relevant doses of nicotine.  
Although similar increases might occur in non-contingent animals after longer 
exposure to nicotine, our data suggest that the sensitivity of nAChRs to 
upregulation is particularly enhanced during the phase of initial exposure to the 
drug.  The finding that cytisine-sensitive [125I]epibatidine binding sites were increased 
in response-dependent mice that were stably self-administering nicotine, as well as in 
animals that did not achieve the acquisition criteria, further supports that it is the 
Athanasios Metaxas 18
contingent relationship between a behavioural response and drug delivery, rather than 
the amount of nicotine-intake, that crucially mediates nicotine-induced 
neurochemistry during the establishment of self-administration behaviour.   
 
Among the regions that responded differently to active and passive nicotine 
administration, the VTA is the biological substrate most likely to be involved in the 
initiation and maintenance of drug-taking behaviour.  The VTA is source of the 
dopaminergic projection to the nucleus accumbens (NAc), and it has been implicated 
in mediating the reinforcing properties of many drugs of abuse, including nicotine (Di 
Chiara, 2000).  Rats will self-administer nicotine directly into the VTA through 
intracranial injections, a behaviour that is attenuated by co-infusion of the β2 subunit 
antagonist dihydro-β-erythroidine, indicating that nicotine’s rewarding effects are 
exerted through nAChRs in this brain region (Corrigall et al., 1994).  Moreover, 
evidence from studies on gain-of-function α4 nAChR subunit knock-in animals 
(Tapper et al., 2004), as well as data from β2 subunit knock-out mice (Picciotto et al., 
1998), further reveals the critical role of VTA α4β2* receptors in mediating nicotine 
reinforcement.  Therefore, our data are not only in keeping with several other lines of 
evidence, but further suggest that the upregulation of α4β2* nAChRs in the VTA is 
not simply an epiphenomenon of nicotine administration, but a key 
neurobiological feature that is critical for mediating nicotine-intake.   
 
A large body of literature suggests that nicotine reinforcement is not only the result of 
the drug’s primary rewarding effects, but also stems from nicotine’s ability to establish 
concurrent stimuli as conditioned reinforcers (reviewed in Chaudhri et al., 2006).  In 
rodents, environmental stimuli promote the rapid acquisition of drug-seeking 
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behaviour (Caggiula et al., 2002), and the maintenance of nicotine self-administration 
during saline substitution (Donny et al., 1999; Martin-Garcia et al., 2009).  Although 
the dissociation of nicotine’s primary reinforcing, from its reinforcement enhancing 
effects was not an aim of our study, our autoradiography data are suggestive of a role 
for the visually paired stimulus in the acquisition of nicotine self-administration.  
Increased cytisine-sensitive [125I]epibatidine binding was observed in self-
administering mice compared to nicotine yoked animals in the DLG, a brain region 
that is dedicated to the processing of visual information.  In cells of the DLG, β2 
subunits have been associated with fast latencies of visual responding, and high 
visually evoked firing rates (Grubb and Thompson, 2004).  Moreover, mouse DLG 
neurons are capable of switching from tonic to burst firing, in order to facilitate signal 
detection (Grubb and Thompson, 2005).  The enhanced density of α4β2* nAChRs in 
this brain area may therefore underlie intense visual information processing, which 
might contribute to the acquisition of self-administration.  In support of this, we have 
previously shown that saline-infused mice that receive a visual cue for active nose-
poking do not acquire self administration behaviour, implying that nicotine-
induced effects on visual processing are important for the acquisition of this 
behaviour (Trigo et al., 2007; Martin-Garcia et al., 2009).  
 
Neuronal nAChRs constitute a heterogeneous family of receptors, which, depending on 
their subunit composition, exhibit distinct physiological and pharmacological 
properties (reviewed in Dani and Bertrand, 2007).  From the present results, we cannot 
exclude that contingent nicotine preferentially increases α4β2* receptor binding, while 
its passive administration regulates other nicotinic subtypes in a similar manner.  
Indeed, cytisine-resistant [125I]epibatidine binding sites correspond to structurally 
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diverse nAChRs subtypes, which require expression of α3, α4, α6, α2, β2, and β4 
subunits (Gotti et al., 2005; Marks et al., 2006).  Although cytisine-resistant nAChR 
density did not differ between animals receiving nicotine in a response-dependent or 
passive manner, subtle differences in the regulation of subunit-specific responses to 
contingent or passive nicotine remain to be examined.  Nevertheless, evidence argues 
against the role of α7 nAChRs in nicotine reinforcement (Walters et al., 2006; Pons et 
al., 2008).  Furthermore, although α6 subunits are involved in acute nicotine self-
administration (Pons et al., 2008), autoradiographic studies on the effects of nicotine 
administration on α6* nAChRs have not yet produced conclusive results (Nguyen et 
al., 2003; Parker et al., 2004; Mugnaini et al., 2006; Even et al., 2008).  In addition, 
α3β4* nAChRs are relatively resistant to up-regulation, both in vivo and in vitro 
(Wang et al., 1998; Davila-Garcia et al., 2003; Nguyen et al., 2003).  It thus seems 
probable that the effects of operant contingency are depicted as changes in cytisine-
sensitive nAChR density in self-administering mice.   
 
Whatever produces neurobiological differences between response-dependent and 
passively received nicotine, it does not seem to engage dopaminergic D1 and D2 
receptors or the dopamine transporters.  In the current study, drug administration did 
not alter D1 receptor or DAT density, and it equally upregulated D2 receptors in 
contingent and non-contingent animals.  As shown by in vivo microdialysis, 
extracellular dopamine levels do not differ between rats self-administering nicotine and 
nicotine-yoked animals, further suggesting that dopaminergic responses to chronic 
nicotine administration are independent of response contingency (Rahman et al., 2004).  
D2 receptors have been implicated in nicotine dependence in both human (McEvoy et 
al., 1995) and animal experiments (Ikemoto et al., 2006).  Radioligand studies, 
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however, have produced conflicting results as to the effect of chronic nicotine on D2 
receptor density.  When delivered through osmotic minipumps, nicotine has been 
shown to decrease (Janson et al., 1992) or produce no differences (Kirch et al., 1992) 
in D2 receptor density.  Therefore, D2 receptor regulation seems to depend on the 
paradigm of nicotine administration employed, as well as on the drug dose and the 
duration of treatment.   
 
In conclusion, our results demonstrate the influence of response-dependency on the 
neurobiological output of nicotine.  Contingent nicotine in self-administering 
animals produced the typical pattern of region-specific upregulation of α4β2* 
nAChRs, whereas the administration of nicotine in a passive manner produced little 
change in the density of cytisine-sensitive receptors.  Importantly, the observation 
that differential regulation of nAChRs takes place in the VTA and the DLG of 
self-administering animals, compared with nicotine-yoked mice, suggests that 
nAChR upregulation in these brain regions is not a by-product of nicotine 
exposure, but a neurobiological feature that crucially determines the acquisition 
and maintenance of nicotine self-administration.  Our data add to the increasing 
evidence that experimenter and self-administered drugs of abuse produce different 
effects (Hemby et al., 1997; Kuzmin and Johansson, 1999; Donny et al., 2000; Lecca et 
al., 2007), and suggest that nicotine-induced neuroadaptation crucially depends on the 
contingent relationship between a subject’s response and the delivery of the reinforcer.    
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TABLES 
saline vs. 
contingent
saline vs.       
non contingent
Medial habenular nucleus (n=6) 7.1 ± 1.8 8.6 ± 2.1 5.9 ± 1.5 20.6 -17.0
Fasciculus retroflexus (n=6) 9.2 ± 1.3 11.2 ± 2.1 11.3 ± 3.4 22.6 23.5
Interpeduncular nucleus (n=6) 10.8 ± 6.0 12.3 ± 3.6 9.9 ± 3.4 13.5 -8.1
Dopaminergic regions
Caudate Putamen (n=10-11) 10.7 ± 0.6 11.4 ± 0.5 10.8 ± 0.4 6.6 0.9
Nucleus accumbens, core (n=9-11) 7.3 ± 0.6 8.0 ± 0.4 7.3 ± 0.3 9.9 1.1
Nucleus accumbens, shell (n=9-11) 7.6 ± 0.6 7.9 ± 0.4 7.5 ± 0.3 3.9 -1.3
Substantia nigra, pars compacta           
(n=9-11) 17.2 ± 1.3 18.7 ± 1.0 17.9 ± 1.2 8.7 4.1
Ventral tegmental area (n=9-11) 16.4 ± 1.2 20.4 ± 1.0* 17.0 ± 1.0# 24.3 3.4
Visual cortex (n=10-11) 9.2 ± 0.4 9.3 ± 0.4 8.8 ± 0.6 1.5 -3.9
Superficial gray layer of the superior 
colliculus (n=9-11) 13.4 ± 1.2 18.2 ± 2.1* 17.2 ± 2.3* 36.2 28.7
Dorsal lateral geniculate nucleus 
(n=10-11) 20.6 ± 0.9 27.8 ± 2.4*** 23.4 ± 1.5
# 35.0 13.6
Ventral lateral geniculate nucleus 
(n=10-11) 17.3 ± 0.7 24.6 ± 1.8*** 21.5 ± 1.5* 42.2 24.3
Accessory olfactory bulb (n=6-11) 6.5 ± 0.8 9.3 ± 2.0 9.2 ± 1.0 43.1 41.5
Insular cortex (n=10-11) 8.8 ± 0.3 9.4 ± 0.5 9.1 ± 0.4 6.8 3.4
Cingulate cortex (n=10-11) 9.5 ± 0.5 9.7 ± 0.5 9.1 ± 0.4 2.6 -3.4
Olfactory tubercle (n=10-11) 8.9 ± 1.0 9.8 ± 0.7 9.9 ± 0.8 10.5 11.6
Lateral posterior thalamic nucleus 
(n=10-11) 18.8 ± 0.9 22.6 ± 1.1* 20.6 ± 1.1 19.8 9.6
Posterior thalamic nuclear group 
(n=10-11) 18.3 ± 0.9 21.4 ± 1.8* 20.7 ± 1.6 17.2 13.2
Medial geniculate nucleus (n=8-11) 19.7 ± 1.1 21.4 ± 1.0 20.3 ± 1.3 8.7 2.8
Intermediate gray layer of the superior 
colliculus (n=9-11) 12.7 ± 1.0 15.8 ± 0.8 13.8 ± 1.2 24.2 8.9
Anteroventral thalamic nucleus             
(n=9-11) 30.4 ± 0.8 31.2 ± 1.6 29.1 ± 2.1 2.5 -4.4
17.2 7.3
Optic tract regions
Other regions
Region
Cytisine-sensitive [125I]epibatidine binding 
(fmol/mg tissue)
% change in binding 
Saline
Mean
Contingent Non Contingent 
Habenulo-interpenducular tract
Table 1 Quantitative autoradiography of cytisine-sensitive [125I]epibatidine binding 
in nicotine contingent, non contingent, and saline treated animals 
Values of cytisine-sensitive [125I]epibatidine binding represent mean ± SEM in brain 
regions of 6 - 11 animals per group.  Self administered nicotine region-specifically 
increased α4β2* nAChRs in the dorsal lateral geniculate nucleus (DLG) and the ventral 
tegmental area (VTA) of self-administering mice, compared to non-contingent animals 
and to saline controls.  *P<0.05, ***P<0.001 vs. saline controls, #P<0.05 vs. contingent 
values, LSD post hoc. 
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saline vs. 
contingent
saline vs.        
non contingent
Medial habenular nucleus 84.1 ± 7.8 85.9 ±7.2 81.1 ±8.2 2.1 -3.5
Fasciculus retroflexus 65.7 ± 5.6 64.6 ±6.9 63.8 ±5.3 -1.7 -2.9
Interpeduncular nucleus 101.2 ± 6.1 99.3 ±6.5 95.1 ±6.9 -1.9 -6.0
Caudate Putamen 2.1 ± 0.2 2.2 ±0.2 2.2 ±0.2 0.5 2.8
Nucleus accumbens, core 2.0 ± 0.3 2.2 ±0.2 2.0 ±0.2 11.1 -1.5
Nucleus accumbens, shell 2.2 ± 0.2 2.1 ±0.2 2.0 ±0.2 -0.9 -5.6
Substantia nigra, pars compacta 5.5 ± 0.9 4.0 ±0.7 3.7 ±0.5* -26.2 -32.1
Ventral tegmental area 6.8 ± 0.3 6.2 ±0.5 5.3 ±0.5 -9.7 -22.6
Visual cortex 0.6 ± 0.1 0.7 ±0.1 0.4 ±0.1 4.8 -29.0
Superficial gray layer of the 
superior colliculus 19.1 ± 1.0 19.3 ±1.5 15.1 ±1.2*** 1.2 -20.6
Dorsal lateral geniculate nucleus 12.2 ± 0.5 11.4 ±0.9 12.7 ±1.0 -5.8 4.3
Ventral lateral geniculate nucleus 12.4 ± 0.6 11.1 ±1.1 12.7 ±1.4 -10.4 2.6
Accessory olfactory bulb 17.2 ± 1.0 15.9 ±1.2 18.2 ±3.3 -7.6 6.4
Insular cortex 0.8 ± 0.1 0.9 ±0.1 0.7 ±0.1 14.6 -17.1
Cingulate cortex 0.7 ± 0.1 0.6 ±0.1 0.6 ±0.1 -8.7 -13.0
Olfactory tubercle 1.2 ± 0.2 1.8 ±0.2 1.4 ±0.2 46.7 13.3
Lateral posterior thalamic nucleus 4.6 ± 0.3 4.7 ±0.4 4.1 ±0.3 2.9 -11.0
Posterior thalamic nuclear group 2.8 ± 0.2 2.9 ±0.2 2.8 ±0.3 5.5 1.8
Medial geniculate nucleus 3.2 ± 0.3 3.2 ±0.3 2.8 ±0.5 0.9 -13.1
Intermediate gray layer of the 
superior colliculus 5.3 ± 1.1 2.7 ±0.3** 2.3 ±0.5*** -49.5 -56.9
Anteroventral thalamic nucleus 4.4 ± 0.6 4.9 ±0.5 4.8 ±0.4 11.6 8.6
-1.1 -10.1Mean
Habenulo-interpenducular tract
Dopaminergic regions
Optic tract regions
Other regions
Region
(fmol/mg tissue)
            Saline Contingent Non Contingent 
Cytisine-resistant [125I]epibatidine binding     % change in binding 
Table 2 Quantitative autoradiography of cytisine-resistant [125I]epibatidine 
binding in nicotine contingent, non contingent, and saline treated animals   
Values of cytisine-resistant [125I]epibatidine binding represent mean ± SEM in brain 
regions of 6 - 11 animals per group.  A significant treatment x region interaction effect 
on cytisine-resistant nAChR density was observed following the administration of 
nicotine.  No differences were observed between animals that stably responded for 
nicotine, and mice that did not achieve acquisition criteria. *P<0.05, **P<0.01, 
***P<0.001 vs. saline controls, LSD post hoc. 
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saline vs. 
contingent
saline vs.       
non contingent
88.9 ± 9.9 108.9 ± 7.0 104.4 ± 4.6 22.5 17.4
Core 76.3 ± 7.6 83.9 ± 12.1 85.7 ± 5.2 10.0 12.4
Shell 74.3 ± 8.5 94.1 ± 6.1 90.6 ± 5.7 26.6 22.0
Caudate Putamen
Rostral part 122.7 ± 12.7 143.0 ± 10.7 143.7 ± 4.2 16.6 17.1
Caudal part 127.1 ± 6.2 137.3 ± 13.5 148.6 ± 5.1 8.0 16.9
32.3 ± 2.7 38.5 ± 1.9 33.9 ± 2.8 19.4 4.9
33.6 ± 2.6 43.0 ± 4.3 38.9 ± 2.2 28.0 16.0
18.7 15.2
Region
Nucleus accumbens
Olfactory tubercle
% change in binding 
Ventral tegmental area
Substantia nigra, pars 
compacta
[3H]raclopride specific binding            
(fmol/mg tissue)
Mean
Saline Contingent Non Contingent 
Table 3 Quantitative autoradiography of D2 receptor binding in nicotine 
contingent, non contingent, and saline treated animals 
Values represent the mean specific binding of [3H]raclopride ± SEM in brain regions 
of 6 animals per group.  A small level of D2 receptor upregulation was observed 
following self-administered and passively received nicotine, but no individual region 
significant increases were observed between groups. 
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saline vs. 
contingent
saline vs.        
non contingent
Core 186.4 ± 24.7 248.4 ± 30.0 246.4 ± 48.2 33.3 32.2
Shell 193.6 ± 23.8 237.0 ± 27.4 236.0 ± 44.9 22.5 21.9
328.1 ± 16.4 359.2 ± 24.5 363.0 ± 37.5 9.5 10.6
309.1 ± 22.6 335.2 ± 31.0 339.9 ± 48.2 8.5 10.0
65.3 ± 3.5 80.2 ± 6.0 68.2 ± 6.4 22.8 4.5
51.2 ± 5.5 55.6 ± 2.2 48.3 ± 6.5 8.7 -5.6
27.6 ± 2.3 30.9 ± 2.1 28.7 ± 1.8 12.0 3.8
27.1 ± 3.9 37.6 ± 2.9 36.8 ± 2.8 38.5 35.7
168.7 ± 15.3 165.3 ± 14.1 190.3 ± 19.2 -2.0 12.9
17.1 14.0Mean
Ventral tegmental area
Substantia nigra
Olfactory tubercle
Saline
Claustrum
Endopiriform nucleus, 
dorsal
Amygadala, total
g
Region
Caudate Putamen
[3H]SCH23390 specific binding               
(fmol/mg tissue)
% change in binding 
Contingent Non Contingent 
Nucleus accumbens
Table 4 Quantitative autoradiography of D1 receptor binding in nicotine 
contingent, non contingent, and saline treated animals  
Values represent the mean specific binding of [3H]SCH23390 ± SEM in brain regions 
of 6 animals per group.  Nicotine self-administration had no effect on D1 receptor 
density. 
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3
saline vs. 
contingent
saline vs.        
non contingent
281.6 ± 41.5 251.0 ± 19.2 298.2 ± 54.6 -10.9 5.9
Core 159.1 ± 25.7 173.0 ± 22.1 219.3 ± 34.3 8.7 37.8
Shell 193.2 ± 33.0 198.5 ± 14.0 227.6 ± 42.4 2.8 17.8
Caudate Putamen
Rostral part 375.2 ± 52.2 447.8 ± 35.4 461.8 ± 38.0 19.4 23.1
Caudal part 367.3 ± 55.3 421.2 ± 29.7 367.9 ± 30.8 14.7 0.2
121.1 ± 21.2 165.8 ± 10.5 162.7 ± 16.2 36.9 34.4
118.2 ± 13.0 128.4 ± 17.7 117.8 ± 11.6 8.6 -0.3
11.9 19.9
Region
[ H]mazindol specific binding               
(fmol/mg tissue)
% change in binding 
Saline Contingent Non Contingent 
Olfactory tubercle
Nucleus accumbens
Ventral tegmental area
Substantia nigra, pars 
compacta
Mean
 Table 5 Quantitative autoradiography of dopamine transporter binding in 
nicotine contingent, non contingent, and saline treated animals  
Values represent the mean specific binding of [3H]mazindol ± SEM in brain regions of 
6 animals per group. Nicotine self-administration had no effect on dopamine 
transporter density. 
LEGENDS TO FIGURES 
Legend to Figure 1 Acquisition and maintenance of nicotine self-administration in 
nicotine contingent and non-contingent C57BL/6J mice.  Data are expressed as mean ± 
SEM of the number of nose pokes in the active and the inactive holes during the 1-hour 
sessions performed over 12 days at 0.03 mg/kg/infusion.  Following day 7, reliable 
drug-taking behaviour was observed in animals receiving response-dependent 
nicotine, which was maintained throughout the duration of this experiment.  The 
mean cumulative nicotine intake throughout the training sessions was at 0.25±0.04 
mg/kg/hr.  n=11 for nicotine-treated animals, n=10 for saline-yoked mice. 
 
Legend to Figure 2 Computer-enhanced colour autoradiograms of total, cytisine-
resistant, and non-specific [125I]epibatidine binding in coronal sections from saline-
treated C57BL/6J mouse brain.  Adjacent sections were incubated for 2 hrs with 100 
pM of [125I]epibatidine alone (first column) or in the presence of 20 nM cytisine 
(second column), and 300 µM (–) nicotine hydrogen tartrate (third column).  Non-
specific binding was indistinguishable from film background.  The majority of 
[125I]epibatidine binding sites were of the cytisine-sensitive, α4β2* subtype.  High 
levels of cytisine-resistant [125I]epibatidine binding were observed in the medial 
habenula, fasciculus retroflexus, and interpeduncular nucleus.  Sections were apposed 
to Kodak BioMax MR-1 film for a period of 6-24 hours.  The colour bar indicates a 
pseudo-colour interpretation of black and white image density, calibrated in fmol/mg 
of tissue equivalent.  The arrows point to areas of measurement for the Caudate 
Putamen (CPu), Medial Habenula (MHb), Lateral Posterior Thalamic Nucleus 
(LPMR), Posterior Thalamic Nuclear Group (Po), Dorsal and Ventral Lateral 
Geniculate Nuclei (DLG & VLG), Ventral Tegmental Area (VTA), Substantia Nigra, 
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pars compacta (SNc), Fasciculus retroflexus (fr), Interpeduncular Nucleus (IP), 
Superficial Gray layer of the Superior Colliculus (SuG), and the  Medial Geniculate 
Nucleus (MG). 
 
Legend to Figure 3 Representative autoradiograms of heteromeric nAChR binding in 
coronal brain sections from nicotine contingent, non contingent, and saline treated 
animals.  The effects of response-contingency on nicotinic receptor binding 
populations are shown at the levels of thalamus (bregma -2.06 mm) and the ventral 
tegmental area (bregma -3.16), following self-administered or passively received 
nicotine.  α4β2* receptor expression was calculated after subtraction of specific 
cytisine-resistant [125I]epibatidine binding from total [125I]epibatidine binding.  
Response-dependent nicotine increased α4β2* receptor binding in the dorsal geniculate 
nucleus and the ventral tegmental area of self-administering mice, compared to yoked 
animals.  The colour bar indicates a pseudo-colour interpretation of black and white 
image density, calibrated in fmol/mg of tissue equivalent.   
 
Legend to Figure 4 Computer-enhanced colour autoradiograms of dopamine D2 (A) 
and D1 receptors (B), and of DA transporters (C), in coronal brain sections from 
nicotine contingent, non contingent, and saline treated animals.  Sections were labelled 
with 4nM [3H]raclopride, [3H]SCH23390, and [3H]mazindol, for D2 and D1 receptors, 
and for the dopamine transporters, respectively.  The horizontal panels show adjacent 
sections cut at the level of the caudate putamen, and of the ventral tegmental area.  
Sections were apposed to Kodak BioMax MR-1 film for a period of 5-6 weeks.  
Specific binding was calculated after subtraction of non-specific binding images from 
total binding images.  No change in D1 and DAT binding was observed among groups.  
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The colour bars indicate a pseudo-colour interpretation of black and white image 
density, calibrated in fmol/mg of tissue equivalent. 
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